| Cat.No. | Name | Information |
|---|---|---|
| M10139 | Anakinra | Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. |
| M6223 | Tocilizumab | Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. Tocilizumab prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the research of rheumatoid arthritis and COVID-19. |
| M6189 | Ossirene | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta (IL-1β) converting enzyme. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene also inhibits Caspase-1. |
| M1622 | Secukinumab | Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is the first-in-class anti-IL-17 agent to be used in studies of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis. |
| M56365 | IL-17 modulator 4 | IL-17 modulator 4 is a proagent of IL-17 modulator 1. IL-17 modulator 1 is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 4 is promising for the research of IL-17A mediated diseases, including inflammation, autoimmune diseases, infectious diseases, cancer, and precancerous syndrome. |
| M55699 | Taurohyodeoxycholic acid sodium | Taurohyodeoxycholic acid (THDCA) sodium prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurohyodeoxycholic acid sodium can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model. |
| M55336 | IL-4-inhibitor-1 | IL-4-inhibitor-1 is the first IL-4 small-molecule inhibitor, with an EC50 of 1.81 µM. IL-4-inhibitor-1 features a nicotinonitrile scaffold with micromolar affinity and potency for the cytokine and disrupts type II IL-4 signaling in cells. |
| M54800 | 13-Methylberberine chloride | 13-Methylberberine chloride is a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS. |
| M54551 | Rademikibart | Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
| M54371 | Erepdekinra | Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist. |
| M54008 | AF12198 | AF12198 is a potent, selective and specific peptide antagonist for human type I interleukin-1 receptor (IL1-R1) (IC50=8 nM) but not the human type II receptor (IC50=6.7 µM) or the murine type I receptor (IC50>200 µM). |
| M53841 | Ac-YVAD-CHO | Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM. |
| M49644 | Lysophosphatidylcholines | Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). |
| M40876 | Ebdarokimab | Ebdarokimab is a monoclonal antibody to IL-12p40/IL-23 that can be used in studies related to inflammatory bowel disease (IBD). |
| M40875 | Brazikumab | Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohn's disease (CD). |
| M40707 | Icotrokinra | Icotrokinra (JNJ-77242113, JNJ-2113) is a novel, orally active IL-23R peptide antagonist for studies related to plaque psoriasis. Icotrokinra exhibits high affinity with human IL-23 receptor hIL-23R with a Kd of 7.1 pM. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in PMBCs (IC50=5.6 pM), and inhibits L-23-induced generation of IFNγ and IL-17A in picomolar levels. |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M30835 | Lipoxin A4 | Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM. |
| M29648 | IL-17 modulator 1 disodium | IL-17 modulator 1 (disodium) is an orally active, highly efficacious IL-17 modulator. IL-17 modulator 1 (disodium) can be used for the research of diseases including psoriasis, ankylosing spondylitis and psoriatic arthritis. |
| M25387 | Daclizumab | Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
